174 related articles for article (PubMed ID: 16706678)
1. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
Gould TD
Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
[TBL] [Abstract][Full Text] [Related]
2. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
5. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Costemale-Lacoste JF; Guilloux JP; Gaillard R
Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.
Li X; Bijur GN; Jope RS
Bipolar Disord; 2002 Apr; 4(2):137-44. PubMed ID: 12071511
[TBL] [Abstract][Full Text] [Related]
7. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
Munch G; Godart N
Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
9. Search for a common mechanism of mood stabilizers.
Harwood AJ; Agam G
Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
[TBL] [Abstract][Full Text] [Related]
10. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice.
Pan JQ; Lewis MC; Ketterman JK; Clore EL; Riley M; Richards KR; Berry-Scott E; Liu X; Wagner FF; Holson EB; Neve RL; Biechele TL; Moon RT; Scolnick EM; Petryshen TL; Haggarty SJ
Neuropsychopharmacology; 2011 Jun; 36(7):1397-411. PubMed ID: 21389981
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
Gould TD; Zarate CA; Manji HK
J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
[TBL] [Abstract][Full Text] [Related]
12. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
[TBL] [Abstract][Full Text] [Related]
13. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
14. Is glycogen synthase kinase-3 a central modulator in mood regulation?
Li X; Jope RS
Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436
[TBL] [Abstract][Full Text] [Related]
15. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
16. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
Ivanova SA; Losenkov IS; Bokhan NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
[TBL] [Abstract][Full Text] [Related]
17. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
Wada A
J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
[TBL] [Abstract][Full Text] [Related]
18. The Wnt signaling pathway in bipolar disorder.
Gould TD; Manji HK
Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
Manduca JD; Thériault RK; Perreault ML
Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
